We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Doxorubicin Plus Sorafenib vs Doxorubicin Alone in Patients With Advanced Hepatocellular Carcinoma: A Randomized Trial.
- Authors
Ahou-Alfa, Ghassan K.; Johnson, Philip; Knox, Jennifer J.; Capanu, Marinela; Davidenko, Irina; Lacava, Juan; Leung, Thomas; Gansukh, Bolorsukh; Saltz, Leonard B.
- Abstract
The article focuses on randomized phase 3 trial which evaluated the efficacy and safety of doxorubicin plus sorafenib compared with doxorubicin alone in patients with advanced hepatocellular carcinoma (HCC). Patients with median age of 65 years and with advanced HCC were randomly assigned to receive doxorubicin intravenously every 21 days plus either sorafenib or placebo rally two times a day. Results indicated that treatment with sorafenib plus doxorubicin compared with doxorubicin monotherapy resulted in greater media time to progression, overall survival and progression-free survival.
- Publication
JAMA: Journal of the American Medical Association, 2010, Vol 304, Issue 19, p2154
- ISSN
0098-7484
- Publication type
Academic Journal
- DOI
10.1001/jama.2010.1672